Global Cancer Antibody Drug Conjugates Market Insights, Forecast to 2025

Table of Contents

1 Study Coverage

• 1.1 Cancer Antibody Drug Conjugates Product
• 1.2 Market Segments
• 1.3 Key Manufacturers Covered
• 1.4 Market by Type
  • 1.4.1 Global Cancer Antibody Drug Conjugates Market Size Growth Rate by Product
  • 1.4.2 First & Second Generation ADCs
  • 1.4.3 Third Generation ADCs
• 1.5 Market by End User
  • 1.5.1 Global Cancer Antibody Drug Conjugates Market Size Growth Rate by End User
  • 1.5.2 Hospitals
  • 1.5.3 Clinics
  • 1.5.4 Other
• 1.6 Study Objectives
• 1.7 Years Considered

2 Executive Summary

• 2.1 Global Cancer Antibody Drug Conjugates Market Size
  • 2.1.1 Global Cancer Antibody Drug Conjugates Revenue 2014-2025
  • 2.1.2 Global Cancer Antibody Drug Conjugates Sales 2014-2025
• 2.2 Cancer Antibody Drug Conjugates Growth Rate by Regions
  • 2.2.1 Global Cancer Antibody Drug Conjugates Sales by Regions
  • 2.2.2 Global Cancer Antibody Drug Conjugates Revenue by Regions

3 Breakdown Data by Manufacturers

• 3.1 Cancer Antibody Drug Conjugates Sales by Manufacturers
  • 3.1.1 Cancer Antibody Drug Conjugates Sales by Manufacturers
  • 3.1.2 Cancer Antibody Drug Conjugates Sales Market Share by Manufacturers
  • 3.1.3 Global Cancer Antibody Drug Conjugates Market Concentration Ratio (CR5 and HHI)
• 3.2 Cancer Antibody Drug Conjugates Revenue by Manufacturers
  • 3.2.1 Cancer Antibody Drug Conjugates Revenue by Manufacturers (2014-2019)
  • 3.2.2 Cancer Antibody Drug Conjugates Revenue Share by Manufacturers (2014-2019)
• 3.3 Cancer Antibody Drug Conjugates Price by Manufacturers
• 3.4 Cancer Antibody Drug Conjugates Manufacturing Base Distribution, Product Types
  • 3.4.1 Cancer Antibody Drug Conjugates Manufacturers Manufacturing Base Distribution, Headquarters
  • 3.4.2 Manufacturers Cancer Antibody Drug Conjugates Product Type
  • 3.4.3 Date of International Manufacturers Enter into Cancer Antibody Drug Conjugates Market
• 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product

• 4.1 Global Cancer Antibody Drug Conjugates Sales by Product
• 4.2 Global Cancer Antibody Drug Conjugates Revenue by Product
• 4.3 Cancer Antibody Drug Conjugates Price by Product

5 Breakdown Data by End User

• 5.1 Overview
• 5.2 Global Cancer Antibody Drug Conjugates Breakdown Data by End User

6 North America

• 6.1 North America Cancer Antibody Drug Conjugates by Countries
  • 6.1.1 North America Cancer Antibody Drug Conjugates Sales by Countries
  • 6.1.2 North America Cancer Antibody Drug Conjugates Revenue by Countries
  • 6.1.3 United States
  • 6.1.4 Canada
  • 6.1.5 Mexico
• 6.2 North America Cancer Antibody Drug Conjugates by Product
• 6.3 North America Cancer Antibody Drug Conjugates by End User

7 Europe

• 7.1 Europe Cancer Antibody Drug Conjugates by Countries
  • 7.1.1 Europe Cancer Antibody Drug Conjugates Sales by Countries
  • 7.1.2 Europe Cancer Antibody Drug Conjugates Revenue by Countries
  • 7.1.3 Germany
  • 7.1.4 France
  • 7.1.5 UK
  • 7.1.6 Italy
  • 7.1.7 Russia
• 7.2 Europe Cancer Antibody Drug Conjugates by Product
• 7.3 Europe Cancer Antibody Drug Conjugates by End User

8 Asia Pacific

• 8.1 Asia Pacific Cancer Antibody Drug Conjugates by Countries
  • 8.1.1 Asia Pacific Cancer Antibody Drug Conjugates Sales by Countries
  • 8.1.2 Asia Pacific Cancer Antibody Drug Conjugates Revenue by Countries
  • 8.1.3 China
  • 8.1.4 Japan
  • 8.1.5 Korea
  • 8.1.6 India
  • 8.1.7 Australia
  • 8.1.8 Indonesia
  • 8.1.9 Malaysia
  • 8.1.10 Philippines
  • 8.1.11 Thailand
  • 8.1.12 Vietnam
  • 8.1.13 Singapore
• 8.2 Asia Pacific Cancer Antibody Drug Conjugates by Product
• 8.3 Asia Pacific Cancer Antibody Drug Conjugates by End User

9 Central & South America

• 9.1 Central & South America Cancer Antibody Drug Conjugates by Countries
  • 9.1.1 Central & South America Cancer Antibody Drug Conjugates Sales by Countries
  • 9.1.2 Central & South America Cancer Antibody Drug Conjugates Revenue by Countries
  • 9.1.3 Brazil
• 9.2 Central & South America Cancer Antibody Drug Conjugates by Product
• 9.3 Central & South America Cancer Antibody Drug Conjugates by End User

10 Middle East and Africa

• 10.1 Middle East and Africa Cancer Antibody Drug Conjugates by Countries
  • 10.1.1 Middle East and Africa Cancer Antibody Drug Conjugates Sales by Countries
  • 10.1.2 Middle East and Africa Cancer Antibody Drug Conjugates Revenue by Countries
  • 10.1.3 GCC Countries
  • 10.1.4 Turkey
  • 10.1.5 Egypt
  • 10.1.6 South Africa
• 10.2 Middle East and Africa Cancer Antibody Drug Conjugates by Product
• 10.3 Middle East and Africa Cancer Antibody Drug Conjugates by End User

11 Company Profiles

• 11.1 Novartis
  • 11.1.1 Novartis Company Details
  • 11.1.2 Company Business Overview
  • 11.1.3 Novartis Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2014-2019)
  • 11.1.4 Novartis Cancer Antibody Drug Conjugates Products Offered
  • 11.1.5 Novartis Recent Development
• 11.2 Merck
  • 11.2.1 Merck Company Details
  • 11.2.2 Company Business Overview
  • 11.2.3 Merck Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2014-2019)
  • 11.2.4 Merck Cancer Antibody Drug Conjugates Products Offered
  • 11.2.5 Merck Recent Development
• 11.3 Roche
  • 11.3.1 Roche Company Details
  • 11.3.2 Company Business Overview
  • 11.3.3 Roche Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2014-2019)
  • 11.3.4 Roche Cancer Antibody Drug Conjugates Products Offered
  • 11.3.5 Roche Recent Development
• 11.4 AbbVie
  • 11.4.1 AbbVie Company Details
  • 11.4.2 Company Business Overview
  • 11.4.3 AbbVie Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2014-2019)
  • 11.4.4 AbbVie Cancer Antibody Drug Conjugates Products Offered
  • 11.4.5 AbbVie Recent Development
• 11.5 UCB
  • 11.5.1 UCB Company Details
  • 11.5.2 Company Business Overview
  • 11.5.3 UCB Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2014-2019)
  • 11.5.4 UCB Cancer Antibody Drug Conjugates Products Offered
  • 11.5.5 UCB Recent Development
• 11.6 Bristol-Myers Squibb
  • 11.6.1 Bristol-Myers Squibb Company Details
  • 11.6.2 Company Business Overview
  • 11.6.3 Bristol-Myers Squibb Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2014-2019)
  • 11.6.4 Bristol-Myers Squibb Cancer Antibody Drug Conjugates Products Offered
  • 11.6.5 Bristol-Myers Squibb Recent Development
• 11.7 Stem CentRx
  • 11.7.1 Stem CentRx Company Details
  • 11.7.2 Company Business Overview
  • 11.7.3 Stem CentRx Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2014-2019)
  • 11.7.4 Stem CentRx Cancer Antibody Drug Conjugates Products Offered
  • 11.7.5 Stem CentRx Recent Development
• 11.8 Biogen Idec
  • 11.8.1 Biogen Idec Company Details
  • 11.8.2 Company Business Overview
  • 11.8.3 Biogen Idec Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2014-2019)
  • 11.8.4 Biogen Idec Cancer Antibody Drug Conjugates Products Offered
  • 11.8.5 Biogen Idec Recent Development
• 11.9 Nordic Nanovector
  • 11.9.1 Nordic Nanovector Company Details
  • 11.9.2 Company Business Overview
  • 11.9.3 Nordic Nanovector Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2014-2019)
  • 11.9.4 Nordic Nanovector Cancer Antibody Drug Conjugates Products Offered
  • 11.9.5 Nordic Nanovector Recent Development
• 11.10 Millennium
  • 11.10.1 Millennium Company Details
  • 11.10.2 Company Business Overview
  • 11.10.3 Millennium Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2014-2019)
  • 11.10.4 Millennium Cancer Antibody Drug Conjugates Products Offered
  • 11.10.5 Millennium Recent Development
• 11.11 Biotest AG
• 11.12 PDL BioPharma
• 11.13 Progenics Pharmaceuticals
• 11.14 Seattle Genetics
• 11.15 Viventia Biotechnologies
• 11.16 AbGenomics Corporation
• 11.17 Helix BioPharma

12 Future Forecast

• 12.1 Cancer Antibody Drug Conjugates Market Forecast by Regions
  • 12.1.1 Global Cancer Antibody Drug Conjugates Sales Forecast by Regions 2019-2025
  • 12.1.2 Global Cancer Antibody Drug Conjugates Revenue Forecast by Regions 2019-2025
• 12.2 Cancer Antibody Drug Conjugates Market Forecast by Product
  • 12.2.1 Global Cancer Antibody Drug Conjugates Sales Forecast by Product 2019-2025
  • 12.2.2 Global Cancer Antibody Drug Conjugates Revenue Forecast by Product 2019-2025
• 12.3 Cancer Antibody Drug Conjugates Market Forecast by End User
• 12.4 North America Cancer Antibody Drug Conjugates Forecast
• 12.5 Europe Cancer Antibody Drug Conjugates Forecast
• 12.6 Asia Pacific Cancer Antibody Drug Conjugates Forecast
• 12.7 Central & South America Cancer Antibody Drug Conjugates Forecast
• 12.8 Middle East and Africa Cancer Antibody Drug Conjugates Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

• 13.1 Market Opportunities and Drivers
• 13.2 Market Challenges
• 13.3 Market Risks/Restraints
• 13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis

• 14.1 Value Chain Analysis
• 14.2 Cancer Antibody Drug Conjugates Customers
• 14.3 Sales Channels Analysis
  • 14.3.1 Sales Channels
  • 14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix

• 16.1 Research Methodology
  • 16.1.1 Methodology/Research Approach
  • 16.1.2 Data Source
• 16.2 Author Details